(Reuters) - Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial. Shares of the company rose 2.4 percent to $31.80 in light trading before the bell. Isis said the drug, codenamed ISIS-APOCIIIRx, was being tested in patients with high to severely elevated triglyceride levels, who were taking another drug to reduce blood fat. Isis's drug raised the level of 'good' cholesterol in the blood by up to 52 percent. ... For full post, click here.
No comments:
Post a Comment